Pyrilutamide
KX-826 · KX826
Last updated
At a glance
Overview
Pyrilutamide (KX-826) is a topical androgen-receptor antagonist being developed for androgenetic alopecia. Human studies exist, but their results and reporting dates differ. Sponsor-reported findings do not establish that retail preparations are equivalent to trial formulations, safer than approved treatments, or effective protection against anabolic-steroid-associated hair loss.
Evidence reviewed October 3, 2026. The March 2026 announcement reported a positive vehicle-controlled study. Kintor's August report still described a planned Chinese drug application separately from cosmetic sales. These documents are not a marketing authorization. March results; August development update.
Limits of this page: the numerical scores, dose tiers, projections, and separately linked protocol, synergy and study records have not been validated by this editorial review. They are not established human treatment instructions. The corrected narrative below does not make those inherited calculations or related records clinically reliable. For a detailed account of the trials, use our pyrilutamide results guide.
How Pyrilutamide works
Mechanism does not establish comparative benefit#
KX-826 is being studied as an antagonist at the androgen receptor. Receptor antagonism differs from inhibiting the enzyme that produces DHT. That distinction does not establish complete scalp restriction, zero systemic exposure, or freedom from sexual, mood or reproductive effects. The sponsor describes low absorption; that description is not proof that risk is absent. Sponsor mechanism and trial summary.
Laboratory receptor measurements cannot rank visible hair regrowth or long-term safety against finasteride, minoxidil or RU58841. A twice-daily study schedule also does not measure a twelve-hour follicular residence time. The reviewed clinical reports do not establish efficacy during anabolic-steroid use.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 1–1 ml | Twice daily | Documented entry-level range |
| Mid | 1–2 ml | Twice daily | Most commonly studied range |
| High | 2–2 ml | Twice daily | Reported study schedules identify trial arms, not approved individual instructions. The numerical dose tiers and linked protocols were not validated by this review. |
Cycle length & outcomes
Documented cycle
24–260 weeks
Plateau after
52 wks
Follow-up is not a guaranteed response timeline#
A 24-week trial endpoint does not mean everyone should wait that long before reporting symptoms. The reviewed evidence does not establish a universal initial-shedding phase, a fixed date for peak regrowth, or a predictable number of months until gains disappear after stopping.
Do not interpret new or worsening symptoms as proof of response. A clinician should assess persistent scalp irritation or unexplained shedding rather than relying on a forum timeline. The existing hair-treatment review guide separates routine assessment from earlier reasons to seek care.
Risks & mistakes
What the reported safety findings can establish#
Kintor reported no drug-related serious adverse events in the March 2026 trial announcement. That is narrower than saying nobody had adverse effects, and it does not establish a lower risk than finasteride. A selected study population and follow-up period cannot rule out every uncommon or delayed harm. March announcement.
The August report also describes a completed longer-term safety study favorably. Its summary is not a complete adverse-event dataset and does not justify the earlier claims of no fertility effects, no monitoring needs or a validated self-adjustment schedule. August report.
Persistent burning, redness, rash, new sexual or mood symptoms, or other unexplained changes deserve clinical assessment. Do not continue or restart a research product simply because a trial summary sounds reassuring. Breathing difficulty or sudden mouth or throat swelling requires emergency medical help. NHS anaphylaxis guidance.
Safety during pregnancy or breastfeeding is not established by these reports; avoid experimental self-treatment and discuss any exposure promptly with a clinician. This review supplies neither a female treatment regimen nor reassurance about fetal or household exposure.
Stack & combine
Multipliers applied when these compounds run together. Values > 1 indicate a bonus on that axis. Tap a partner to expand the mechanism.
| Partner | Type | Lean | Fat loss | Recovery |
|---|---|---|---|---|
| synergistic | ×1.00 | ×1.00 | ×1.00 |
FAQ — Pyrilutamide
Research & citations
5 studies cited on this page.
Conclusion
Pyrilutamide has a human research program and encouraging sponsor-reported findings, alongside an earlier trial that did not separate significantly from vehicle. Important questions about comparative benefit, long-term risks and commercial-formulation equivalence remain. Take the actual study and product information to a dermatologist; do not use inherited dose tiers or forum stacks as an established treatment plan.